

Intrarosa[™] (prasterone) – New Drug Approval

- On November 17, 2016, the <u>FDA announced</u> the <u>approval</u> of Endoceutics' <u>Intrarosa (prasterone)</u>, for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), due to menopause.
- Approximately 50% of postmenopausal women suffer from <u>VVA</u>. The symptoms of VVA are vaginal dryness, pain during sexual activity (dyspareunia) and irritation and itching.
- Intrarosa contains the active ingredient, prasterone that is also known as dehydroepiandrosterone (DHEA). Prasterone is an inactive endogenous steroid and is converted into active androgens and/or estrogens.
 - Although DHEA is included in some dietary supplements, the efficacy and safety of those products have not been established for diagnosing, curing, mitigating, treating or preventing any disease.
- The efficacy of Intrarosa was evaluated in two 12-week placebo-controlled trials enrolling 813
 postmenopausal women with moderate to severe dyspareunia. The four co-primary efficacy endpoints
 were severity of dyspareunia, the % of vaginal superficial cells, the % of parabasal cells, and vaginal pH.
 - The mean change in severity of dyspareunia was -0.87 vs. -1.27 (p = 0.0132) in trial 1 and -1.06 vs. -1.42 (p = 0.0002) in trial 2 for placebo vs. Intrarosa, respectively.
 - The mean change in % superficial cells was 0.91% vs. 5.62% (p < 0.0001) in trial 1 and 1.75% vs. 10.2% (p < 0.0001) in trial 2 for placebo vs. Intrarosa, respectively.
 - The mean change in % parabasal cells was -1.62% vs. -47.4% (p < 0.0001) in trial 1 and -11.98% and -41.51% (p < 0.0001) in trial 2 for placebo vs. Intrarosa, respectively.
 - The mean change in vaginal pH was -0.21 vs. -1.04 (p < 0.0001) in trial 1 and -0.27 vs. -0.94 (p < 0.0001) in trial 2 for placebo vs. Intrarosa, respectively.
- Intrarosa is contraindicated in patients with undiagnosed abnormal genital bleeding.
- Other warnings and precautions of Intrarosa include current or past history of breast cancer.
- The most common adverse events (≥ 2%) with Intrarosa use were vaginal discharge and abnormal Pap smear.
- The recommended dose of Intrarosa is one vaginal insert once daily at bedtime.
- Endoceutics' launch plans for Intrarosa are pending. Intrarosa will be available as 6.5 mg vaginal inserts.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.